What Exit Interviews Add to GLP-1 Trials

A new qualitative study asked 60 people who had completed the ACHIEVE-3 type 2 diabetes trial what they noticed beyond blood sugar and weight. The study found that participants often named perceived energy, appetite or cravings, movement, and psychological changes alongside those familiar trial outcomes.^[1] It is useful patient-experience evidence, but it is not a head-to-head result showing that one oral GLP-1 medicine produced better experiences than another.^[1][2]

ACHIEVE-3 compared oral orforglipron with oral semaglutide in adults whose type 2 diabetes was inadequately controlled with metformin. The registered phase 3 trial was randomized and open label, enrolled 1,698 participants, and measured change in HbA1c, a marker of average blood glucose over time, at week 52 as its primary outcome.^[2] The newer paper is a separate exit-interview study within that trial setting.^[1]

What the interviews asked

The researchers recruited people from ten US clinical sites who had taken an ACHIEVE-3 study medicine for at least three months and had at least 75% study-drug compliance. Interviews were conducted in English or Spanish after the treatment period, audio-recorded, transcribed, and analysed for positive treatment benefits reported by participants.^[1] This approach collects descriptions in participants' own words instead of asking only whether a laboratory value changed.^[1]

The 60 interview participants had a mean age of 59.1 years, and 28 were female. Their mean HbA1c fell by 1.6 percentage points from a baseline of 8.3%, while mean weight fell by 4.7 kg from a baseline of 96.0 kg. Those figures describe the interview sample, not a treatment recommendation or an estimate of what will happen for an individual patient.^[1]

The background matters because ACHIEVE-3 used four oral treatment groups: two target doses of orforglipron and two of oral semaglutide. The interview team was blind to dose assignment while enrolling participants. The qualitative study therefore sits alongside the randomized trial; it does not turn participant accounts into a new direct comparison of those medicines.^[1][2]

What participants reported

Controlled HbA1c and weight reduction were the most frequently reported positive changes, named by 53 and 50 participants respectively. Beyond those outcomes, 28 participants reported increased perceived energy, 23 reported reduced appetite and cravings, and 18 each reported improved exercise or movement and psychological improvements.^[1] The study reports what this selected group said they experienced. It does not establish that each reported change was caused only by the medicine.^[1]

Satisfaction was also high in the interview sample: all 60 rated their overall trial satisfaction as 4 or 5 on a five-point scale, and 50 said they were very willing to continue the same trial treatment. The paper reports these results across the interview study, not as a drug-specific patient-satisfaction comparison between orforglipron and oral semaglutide.^[1]

Why patient experience belongs beside trial endpoints

A clinical endpoint measures a defined outcome. A patient-experience study can add context about daily function, treatment burden, symptoms, or priorities that a primary endpoint may not capture. The European Medicines Agency's reflection paper says patient experience data can inform medicine development, regulatory assessment, and later clinical decision-making, while the method and question still need to fit the evidence being sought.^[3]

For people following oral GLP-1 research, that distinction keeps the headline in proportion. This paper suggests that participants valued changes such as energy and appetite alongside HbA1c and weight. The ACHIEVE-3 registry remains the better source for the randomized trial's design and primary efficacy comparison involving oral semaglutide.^[1][2] Our semaglutide regulation guide covers a different question: the legal and prescription status of semaglutide depends on jurisdiction.

What we do not yet know

The exit interviews were not designed to answer every question about treatment experience. The paper says its interview guide did not directly ask about negative treatment experiences, although participants could report them spontaneously. It also relied on spontaneous reports of changes, did not include direct probes about issues specific to oral GLP-1 medicines, and most interviews took place two to four weeks after trial exit. A reader comparing oral semaglutide with another medicine needs evidence that directly tests that comparison.^[1]

The authors also disclose that three authors worked for Thermo Fisher Scientific, which Eli Lilly paid to conduct the study, and that two authors were Eli Lilly employees and shareholders.^[1] That disclosure does not invalidate the interviews, but readers should keep the study's sponsor relationship and its positive-question design in view when interpreting the findings.^[1]

Why this matters

HbA1c and body weight remain central outcomes in type 2 diabetes trials. These interviews add a narrower finding: some participants described daily changes that mattered to them and may help researchers decide what to measure in future studies. If you are considering any GLP-1 medicine, including semaglutide, discuss the evidence, adverse effects, other medicines, and your own treatment goals with a qualified clinician. An interview study should not guide someone to choose or dose a product.^[1][3]